Turning Point Therapeutics IncTurning Point Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The analysis of Turning Point Therapeutics Inc is prepared by All Street Sevva using cutting edge Cognitive Robots. Browse to the end of this webpage for potential risks for Turning Point Therapeutics Inc based on sector, location and marketcap. This Disclosure score covers 17 UN SDGs including: 'Zero Hunger', 'Industry, Innovation & Infrastructure' and 'Life below Water'.

Turning Point Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 1.3, social score of 1.1 and governance score of 4.0.

SDG Transparency Score for Turning Point Therapeutics Inc 

2.1

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Turning Point Therapeutics Inc 
1.3

Environmental

1.1

Social

4.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1551Voyager Life PLC
2.2
Medium
1551Source Natural Foods and Herbal Supplements Ltd
2.2
Medium
1571Turning Point Therapeutics Inc
2.1
Medium
1571Cerevel Therapeutics Holdings Inc
2.1
Medium
1571Charlotte's Web Holdings Inc
2.1
Medium
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Turning Point Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Turning Point Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Turning Point Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Turning Point Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Turning Point Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Turning Point Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Turning Point Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.

Sorry!

Failed to process!